The mental health industry watchdog Citizens Commission on Human Rights International (CCHR) warns that organized psychiatry's long history of downplaying risks associated with psychiatric drugs could thwart or weaken the Department of Health and Human Services' May 2026 plan to address overprescribing and support safe deprescribing of antidepressants. CCHR urges federal officials to implement stronger protections for informed consent and patient safety.
The federal shift toward deprescribing aligns with international concerns, such as the 2024 UK All-Party Parliamentary Group report, which called for deprescribing antidepressants and creating withdrawal support services. Yet some within U.S. psychiatry minimize legitimate concerns about antidepressants and cite workforce shortages and limited beds, which CCHR sees as a thinly veiled request for more funding. This stance persists despite mental health spending skyrocketing 241% from $40.9 billion in 2000 to $139.6 billion in 2021, while outcomes have worsened, as highlighted in an April 2026 U.S. House Subcommittee roundtable.
Following HHS consumer-protection plans, a psychiatric committee formed in 2025 to counter these initiatives and recently conducted a highly selective survey at a major psychiatric annual meeting. Of 229 psychiatrists who responded, 94% disagreed that the HHS reforms would help their field. CCHR sees this as an exercise designed to manufacture opposition to deprescribing in order to protect antidepressant prescribing.
In 2002, a psychiatric leader who now serves as secretary of that committee was president and CEO of a major psychiatric hospital in Maryland, where clinical drug trials were conducted under contracts from multiple pharmaceutical companies. A high-profile mass shooter was once treated at this hospital, where he was prescribed antidepressants linked to violent and suicidal behavior. In 2004, the psychiatrist formally opposed an FDA Black Box warning on SSRI antidepressants and suicide risk in children, issuing a joint statement expressing deep concern that a black-box warning might have a chilling effect on prescribing.
In 1991, CCHR's actions prompted an FDA public hearing into antidepressants linked to suicide and violence, where testimony from patients and families was ignored by a panel of psychiatrists. In 2004, CCHR again assisted families who testified before another FDA hearing on antidepressants inducing suicide, which contributed to the Black Box suicide warning issued in October that year. The chief communications officer of the main psychiatric body acknowledged CCHR as an opponent due to its well-publicized campaign. Between 1998 and 2002, some two million commercially insured pediatric beneficiaries were taking antidepressants, with preschoolers aged 0-5 years as the fastest-growing segment.
Jan Eastgate, President of CCHR International, said, "For years, the mental health field touted the mantra that depression was caused by a chemical imbalance — a claim CCHR refuted since the first SSRI antidepressant came on the market in 1988." In 2001, patient materials from a psychiatric professional body stated that antidepressants "may be prescribed to correct imbalances in the levels of chemicals in the brain" and are not "habit-forming." In May 2005, CCHR organized a joint letter to the FDA signed by more than 100 doctors, stating that such advertisements were not supported by science and misled patients. A major 2022 University College London umbrella review in Molecular Psychiatry delivered irrefutable evidence disproving the serotonin theory of depression.
Psychiatric organizations have consistently downplayed risks, including potential violence and withdrawal symptoms, now widely recognized. Withdrawal risks were minimized, with patients experiencing severe symptoms often misdiagnosed as relapsing. In 2026, Psychiatric Times admitted these risks had been routinely denied, minimized, or reframed. Eastgate warns: "Given this decades-long pattern of downplaying risks, opposing warnings and maintaining pharmaceutical relationships, claims that organized psychiatry will genuinely support the current Administration's deprescribing efforts lack credibility."
